Dramatic Volume Reduction of a Large GH/TSH Secreting Pituitary Tumor with Short Term Octreotide Therapy
Tóm tắt
A case is presented of a huge GH/TSH secreting tumor and marked volumetric reduction in size with only one week of Octreotide therapy. To our knowledge, this is the first reported case of such a dramatic volumetric response to short-term Octreotide therapy.
Tài liệu tham khảo
Barkan A, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:1040–1048.
Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegaly patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000;85:4099–4103.
Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-1, and tumour size. J Clin Endocrinol Metab 2002;87(10):4554–4563.
Colao A, Ferone D, Cappabianca P, et al. Effects of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82:3308–3314.
Colao A, Ferone F, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779–2786.
Cozzi R, Barausse M, Sberna M, et al. Lanreotide 60 mg, a longer-acting somatostatin analog: Tumor shrinkage and hormonal normalization in acromegaly. Pituitary 2000;3:231–238.
Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681–699.
James RA, Chatterjee S, White MC, Hall K, Moller N, Kendall-Tyler P. Continuous infusion of octreotide in acromegaly. Lancet 1989;2(8761):1083–1087.
Lundin P, Engstrom BE, Karlsson FA, et al. Longterm octreotide therapy in growth hormone-secreting pituitary adenomas: Evaluation with serial MR. Am J Neuroradiol 1997;18:765–772.
Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034–3040.
Sassolas G, Harris AG, James-Didier A, the French SMS 201–995 acromegaly study group. Longterm effect of incremental doses of the somatostatin analog SMS 201–995 in 58 acromegalic patients. J Clin Endocrinol Metab 1990;71:391–397.
Vance ML, Harris AG. Longterm treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med 1991;151:1573–1578.
Lindsay JR, Harding JA, Ellis PK, Sheridan B, Atkinson AB. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with Octreotide in the absence of marked tumour shrinkage. Pituitary 2003;6:209–214.